Le Lézard
Classified in: Health, Science and technology
Subject: LICENSING AGREEMENTS

Beleave Provides Update on Manitoba Retail Licensing Agreement


TORONTO, March 01, 2018 (GLOBE NEWSWIRE) -- Beleave Inc. ("Beleave" or the "Company") (CSE:BE); (OTCQX:BLEVF) would like to provide an update with regard to recent retail licensing grants in the province of Manitoba.  On January 3rd, 2018 the Company announced that it had signed a letter of intent with Seven Oaks of Manitoba to supply 1.25 million grams of dry cannabis flower or equivalent.  The transaction was contingent on Seven Oaks' ability to obtain a retail license from the government of Manitoba, however they did not obtain it in this round of licensing.   

"We maintain that Seven Oaks would have been a great choice retail partner for us in Manitoba but understand licenses were limited and the environment highly competitive," commented Beleave Chief Executive Officer Andrew Wnek. "The team is actively exploring partnership opportunities in all provinces and will continue to do so in Manitoba and stand behind Seven Oaks as they further explore other distribution and retail prospects."

In addition the company would like to congratulate the four companies that were chosen to open Manitoba's retail distribution locations.

About Beleave
Beleave Inc. is a biotech company and Beleave's wholly-owned subsidiary Beleave Kannabis Corp. (formerly First Access Medical Inc.) is a licensed producer pursuant to the ACMPR. Beleave's purpose-built facility is located in Hamilton, Ontario.


For further information please contact:


Sebastian de Kloet
Phone: (905) 979 - 5173 
Email: [email protected]
beleave.com
  
 

Forward-Looking Statements

This news release contains "forward-looking information" within the meaning of applicable securities law ("forward-looking statements"). The use of any of the words "plan", "anticipate", "continue", "estimate", "expect", "may", "will", "project", "should", "believe" and other similar words, or statements that certain events or conditions "may" or "will" occur are intended to identify forward-looking information. These statements are only predictions. Although the Company believes that the expectations and assumptions on which the forward-looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because the Company can give no assurance that they will prove to be correct. These risks and uncertainties include, but are not limited to, the Company's ability to satisfy the conditions associated with its cultivation license, the Company's ability to obtain a sales license and the related timing considerations, the availability of further financing, consumer interest in its products, competition, regulation, operational and technological risks, and anticipated and unanticipated costs and delays. Since forward-looking information addresses future events and conditions, by its very nature it involves inherent risks and uncertainties. This information speak only as of the date of this news release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Company's disclosure documents, which can be found under the Company's profile on www.sedar.com.


These press releases may also interest you

19 avr 2024
Remedium Healthcare Products is proud to announce the launch of NuVeria Labs' revolutionary Sacral Silicone Dressing, now available for purchase on Amazon, bringing advanced wound care solutions directly to consumers' doorsteps. Designed to address...

19 avr 2024
Getting specialty medications into...

19 avr 2024
Arthrex, a global leader in minimally invasive surgical technology, has once again taken home prestigious medals for product innovation at the 37th annual Edison Awards. "This product, along with our other innovations,...

19 avr 2024
Aligned with the trend of immersive water therapy in 2024, Baros Maldives' Serenity Spa stands out as an oasis of indulgent spa and beauty rituals, boasting a 50-year legacy of luxury. Nestled within a tranquil sanctuary amidst the lush Maldivian...

19 avr 2024
Oragenics, Inc. , a company focused on developing unique, intranasal pharmaceuticals for the treatment of neurological disorders, today announced that it received a notice (the "Notice") from the NYSE American LLC (the "NYSE American") dated April...

19 avr 2024
Building on a successful phase one in which STChealth proved that the Universal Patient Identifier (UPI)?powered by Experian Health's Universal Identity Manager (UIM) and NCPDP Standardstm?can accurately identify patients across multiple datasets in...



News published on and distributed by: